Zusammenfassung
Antikoagulantien und Thrombozytenaggregationshemmer werden in steigendem Umfang bei Thrombosen, Embolien und arteriellen Gefäßkrankheiten mit unterschiedlichen therapeutischen Schwerpunkten eingesetzt. Die akute Antikoagulation mit Heparin und die nachfolgende Gabe oraler Vitamin-K-Antagonisten ist die Standardtherapie für akute Venenthrombosen und Lungenembolien. Daneben werden orale Antikoagulantien zur Prophylaxe kardiogener Hirnembolien bei atrialen Thromben und bei arteriosklerotisch bedingten Karotisstenosen angewendet. Niedermolekulare Heparine werden überwiegend zur Prophylaxe thromboembolischer Komplikationen bei immobilisierten Patienten, aber auch zunehmend für die Therapie tiefer Venenthrombosen bei ambulanten Patienten eingesetzt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Antiplatelet Trialists’ Collaboration (1994): Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Brit. Med. J. 308: 81–106.
Born G.V.R., Collins R. (1997): Aspirin versus clopidogrel: the wrong question? Lancet 349: 806–807.
Bousser M.G., Eschwege E., Haguenau M., Lefauconnier J.M., Thibult N. et al. (1983): „AICLA“ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14: 5–14.
CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339.
Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143: 1–13.
Enserink M. (1996): Fraud and ethics charges hit stroke drug trial. Science 274: 2004–2005.
Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C. et al. (1989): The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet I: 1215–1220.
Gorelick P.B., Born G.V.R., d’Agostino R.B., Hanley D.F. Jr., Moye L., Pepine C.J. (1999): Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. Stroke 30: 1716–1721.
Hass W.K., Easton J.D., Adams H.P. Jr., Pryse-Phillips W., Molony B.A. et al. (1989): A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321: 501–507.
Hirsh J., Levine M.N. (1992): Low molecular weight heparin. Blood 79: 1–17.
Klimt C.R., Knatterud G.L., Stamler J., Meier P. (1986): Persantine-aspirin reinfarction study. Part II. Secondary coronary prevention with persantine and aspirin. J. Am. Coll. Cardiol. 7: 251–269.
Kock H.-J., Schmit-Neuerburg K.P., Hanke J., Rudofsky G., Hirche H. (1995): Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. Lancet 346: 459–461.
Koopman M.M.W., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M. et al. (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N. Engl. J. Med. 334: 682–687.
Leizorovicz A., Haugh M.C., Chapuis F.-R., Samama M.M., Boissel J.-P. (1992): Low molecular weight heparin in prevention of perioperative thrombosis. Brit. Med. J. 305: 913–920.
Lensing A.W.A., Prins M.H., Davidson B.L., Hirsh J. (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch. Intern. Med. 155: 601–607.
Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K.L. et al. (1998): A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. N. Engl. J. Med. 339: 1665–1671.
Levine M., Gent M., Hirsh J., Leclerc J., Anderson D. et al. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334: 677–681.
Moussa I., Oetgen M., Roubin G., Colombo A., Wang X., Iyer S. et al. (1999): Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99: 2364–2366.
The Persantine-Aspirin Reinfaction Study Research Group (1980): Persantine and aspirin in coronary heart disease. Circulation 62: 449–461.
Wenzel E., Keller-Stanislawski B., Tiaden J.D., Mörsdorf S., Pindur G., Graul A., Seyfert U.T. (1999): Antithrombotische, blutstillende und antianämische Mittel. In: Müller-Oerlinghausen B. et al. (Hrsg.): Handbuch der unerwünschten Arzneimittelwirkungen. Urban & Fischer, München.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2001). Antikoagulantien und Thrombozytenaggregationshemmer. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56832-9_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-56832-9_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67573-0
Online ISBN: 978-3-642-56832-9
eBook Packages: Springer Book Archive